查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842069

美国医疗CDMO（受託製造厂商）市场：市场规模、份额和趋势分析（按类型、产品、服务、工作流程、治疗领域和最终用途划分），按细分市场预测（2025-2033年）

U.S. Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Service, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国医疗CDMO市场概览

美国医疗 CDMO（受託製造厂商）市场预计在 2024 年达到 653 亿美元，预计到 2033 年将达到 1,442 亿美元，2025 年至 2033 年的复合年增长率为 9.41%。

由于对包括生技药品、生物相似药以及细胞和基因疗法在内的先进疗法的需求不断增长，美国医疗保健CDMO市场正在快速扩张。此外，製药公司日益关注肿瘤学、罕见疾病和免疫学领域的研发，这需要高度专业化的生产製造技术。

CDMO（合约研发生产机构）提供许多公司内部缺乏的关键基础设施、扩充性和技术能力。强劲的研发管线、生技药品专利到期以及个人化医疗的加速发展进一步推动了CDMO的成长。这使得CDMO成为加速复杂治疗药物研发速度、降低成本并实现合规生产的重要合作伙伴。製药和生物技术公司与CDMO合作，以降低营运成本并加速产品开发。此外，CDMO服务的兴起也得益于以下事实：建立内部生产设施需要大量的资金投入、员工培训和合规性审查，这可能会减缓创新。

此外，CDMO 为製药和医疗设备公司提供先进技术、大规模生产设施和灵活生产模式的即时获取途径。这种伙伴关係最大限度地降低了财务风险，使製药公司能够专注于核心研发，同时利用 CDMO 进行临床和商业化生产。在竞争激烈的市场中，速度至关重要，CDMO 提供了一条敏捷且经济高效的途径，能够更快地将药物推向市场，从而确保竞争优势和盈利。

美国医疗产业在FDA和全球法规的严格框架下运作，要求严格遵守GMP标准、验证和文件记录。此外，满足这些合规要求对製药公司而言可能耗费大量资源。然而，CDMO拥有深厚的监管专业知识、完善的品质系统以及丰富的全球申请管理经验，可以降低延误和违规的风险。 CDMO持续满足不断变化的监管标准的能力有助于建立信任和信心。此外，CDMO正在投资数位化、自动化和数据主导的合规系统，并加强监管。这些监管方面的专业知识使CDMO成为重要的策略合作伙伴，使製药公司能够专注于创新，同时确保产品品质和病患安全。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：美国医疗CDMO市场：驱动因素、趋势与范围

  • 市场关联性展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 技术格局
  • 定价模式分析
  • 关税影响分析
  • 价值链分析
    • 供应趋势
    • 需求趋势
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析与SWOT分析

第四章：美国医疗CDMO市场：按类型分類的估算与趋势分析

  • 美国医疗CDMO市场：按类型分類的概览
  • 美国医疗CDMO市场：按类型分類的变化分析
  • 按类型（2021-2033 年）
  • 低分子
    • 品牌
    • 非专利的
  • 聚合物
    • 生技药品
    • 生物相似药
  • 医疗设备
    • 诊断
    • 治疗

第五章：美国医疗CDMO市场：按产品分類的估算与趋势分析

  • 美国医疗CDMO市场：产品概览
  • 美国医疗CDMO市场：按产品分類的变化分析
  • 依产品划分（2021-2033 年）
  • 製药
    • API
    • 製药
  • 医疗设备
    • 一级
    • II 类
    • III 类

第六章：美国医疗CDMO市场：按服务类型分類的估算与趋势分析

  • 美国医疗保健CDMO市场：按服务分类的仪表板
  • 美国医疗保健CDMO市场：按服务分類的变化分析
  • 依服务年资（2021-2033）
  • 合约开发
    • 预配方和配方开发服务
    • 製程开发与最佳化
    • 分析测试和方法检验
    • 规模化和技术转移
  • 契约製造
    • 原料药（API）生产
    • 成品药生产
    • 医疗设备和复杂产品
  • 包装和标籤
  • 监管事务
  • 其他的

第七章：美国医疗CDMO市场：依工作流程分類的估算与趋势分析

  • 美国医疗CDMO市场：工作流程仪錶板
  • 美国医疗CDMO市场：按工作流程分類的差异分析
  • 按工作流程（2021-2033）
  • 临床
  • 上市

第八章：美国医疗CDMO市场：按治疗领域分類的估算与趋势分析

  • 美国医疗保健CDMO市场：治疗领域概览
  • 美国医疗保健CDMO市场：按治疗领域分類的趋势分析
  • 依治疗领域划分（2021-2033 年）
  • 瘤
  • 感染疾病
  • 神经系统疾病
  • 心血管疾病
  • 代谢紊乱
  • 自体免疫疾病
  • 呼吸系统疾病
  • 眼科
  • 胃肠道疾病
  • 整形外科疾病
  • 牙科疾病
  • 其他的

第九章：美国医疗CDMO市场：依最终用途分類的估算与趋势分析

  • 美国医疗CDMO市场：按最终用途分類的概览
  • 美国医疗CDMO市场：按最终用途分類的变化分析
  • 依最终用途划分（2021-2033 年）
  • 製药和生物技术公司
  • 医疗设备公司
  • 其他的

第十章 竞争格局

  • 主要参与者的分类
    • 市场领导
    • 新兴企业
  • 市占率/估值分析（热力图分析），2024 年
  • 公司简介
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc.
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International
Product Code: GVR-4-68040-749-6

U.S. Healthcare Contract Development And Manufacturing Organization Market Summary

The U.S. healthcare contract development and manufacturing organization market size was estimated at USD 65.3 billion in 2024 and is projected to reach USD 144.2 billion by 2033, growing at a CAGR of 9.41% from 2025 to 2033. The U.S. healthcare CDMO market is expanding rapidly, driven by rising demand for biologics, biosimilars, and advanced therapies, including cell and gene therapies. Besides, pharmaceutical companies are increasingly focused on R&D in oncology, rare diseases, and immunology, creating the need for highly specialized manufacturing expertise.

CDMOs provide critical infrastructure, scalability, and technical capabilities that many firms lack internally. Growth is further reinforced by strong pipeline activity, patent expirations of biologics, and the acceleration of personalized medicine. This has led CDMOs to become essential partners in enabling faster development timelines, cost efficiency, and compliant production of complex therapies. Pharmaceutical and biotech companies are partnering with CDMOs to reduce operational costs and accelerate product development. Besides, among pharmaceutical companies, establishing in-house facilities requires substantial capital investment, workforce training, and regulatory compliance, which may slow innovation, which has further led to the rise of CDMO services.

In addition, CDMOs offer pharmaceutical and medical device companies' immediate access to advanced technologies, large-scale facilities, and flexible production models. This partnership supports minimizing the financial risks and allows pharma companies to focus on core R&D while leveraging CDMOs for clinical and commercial manufacturing. In a highly competitive market where speed is critical, CDMOs offer an agile and cost-efficient pathway to bring drugs to market faster, ensuring competitive advantage and profitability.

The U.S. healthcare industry operates under stringent FDA and global regulatory frameworks, requiring strict adherence to GMP standards, validation, and documentation. Besides, navigating these compliance requirements can be highly resource-intensive for pharma companies. CDMOs, however, possess deep regulatory expertise, established quality systems, and experience managing global submissions, reducing the risk of delays and non-compliance. Their ability to consistently meet evolving regulatory standards enhances trust and reliability. In addition, CDMOs are investing in digitalization, automation, and data-driven compliance systems to strengthen oversight. This regulatory know-how makes CDMOs indispensable strategic partners, enabling pharma companies to focus on innovation while ensuring product quality and patient safety.

U.S. Healthcare Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. healthcare contract development and manufacturing organization market report based on type, product, service, workflow, therapeutic area, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecule
  • Branded
  • Generic
  • Large Molecule
  • Biologics
  • Biosimilar
  • Medical Device
  • Diagnostics
  • Therapeutics
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical
  • API
    • Traditional API
    • HP-API
    • Biologics
    • Others
  • Drug Product
    • Oral topical dose
    • Semi-solid dose
    • Liquid dose
    • Others
  • Medical Devices
  • Class I
  • Class II
  • Class III
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
  • Pre-formulation & Formulation Development Service
  • Process Development & Optimization
  • Analytical Testing & Method Validation
  • Scale-up & Tech Transfer
  • Contract Manufacturing
  • API Manufacturing
  • Finished drug products Manufacturing
  • Medical Devices & Combination Products
  • Packaging and labelling
  • Regulatory Affairs
  • Others
  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Others

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. Workflow
    • 1.2.5. Therapeutic Area
    • 1.2.6. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Healthcare Contract Development and Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Healthcare Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
  • 4.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
  • 4.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Branded
      • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Generic
      • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilar
      • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medical Device
    • 4.6.1. Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Diagnostics
      • 4.6.2.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Therapeutics
      • 4.6.3.1. Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Healthcare Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
  • 5.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
  • 5.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
  • 5.4. Pharmaceutical
    • 5.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. API
      • 5.4.2.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.2. Traditional API
        • 5.4.2.2.1. Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.3. HP-API
        • 5.4.2.3.1. HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.4. Biologics
        • 5.4.2.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.5. Others
        • 5.4.2.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Drug Product
      • 5.4.3.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.2. Oral Topical Dose
        • 5.4.3.2.1. Oral Topical Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.3. Semi-Solid Dose
        • 5.4.3.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.4. Liquid Dose
        • 5.4.3.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.3.5. Others
        • 5.4.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Medical Devices
    • 5.5.1. Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Class I
      • 5.5.2.1. Class I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Class II
      • 5.5.3.1. Class II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Class III
      • 5.5.4.1. Class III Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Healthcare Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
  • 6.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
  • 6.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Preformulation & Formulation Development Service
      • 6.4.2.1. Preformulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Process Development & Optimization
      • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Analytical Testing & Method Validation
      • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Scale-up & Tech Transfer
      • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. API Manufacturing
      • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Finished drug products Manufacturing
      • 6.5.3.1. Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. Medical Devices & Combination Products
      • 6.5.4.1. Medical Devices & Combination Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Packaging and Labelling
    • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Regulatory Affairs
    • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

  • 7.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
  • 7.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
  • 7.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 7.4. Clinical
    • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Commercial
    • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
  • 8.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
  • 8.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Infectious Diseases
    • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Neurological Disorders
    • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Cardiovascular Disease
    • 8.7.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Metabolic Disorders
    • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Autoimmune Diseases
    • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Respiratory Diseases
    • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Ophthalmology
    • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Gastrointestinal Disorders
    • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Orthopedic Diseases
    • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.14. Dental Diseases
    • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.15. Others
    • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Healthcare Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
  • 9.2. U.S. Healthcare Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
  • 9.3. U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biotechnology Companies
    • 9.4.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Key Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Catalent Inc.
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Lonza
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Recipharm AB
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Siegfried Holding AG
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Thermo Fisher Scientific, Inc.
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Labcorp Drug Development
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Jabil Inc
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Syngene International Limited
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. IQVIA Inc.
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Almac Group
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Ajinomoto Bio-Pharma
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Adare Pharma Solutions
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Alcami Corporation
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Vetter Pharma International
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 5 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 7 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Healthcare Contract Development and Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Healthcare Contract Development and Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Healthcare Contract Development and Manufacturing Organization Market: Type outlook and key takeaways
  • Fig. 20 U.S. Healthcare Contract Development and Manufacturing Organization Market: Type movement analysis
  • Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Healthcare Contract Development and Manufacturing Organization Market: Product outlook and key takeaways
  • Fig. 31 U.S. Healthcare Contract Development and Manufacturing Organization Market: Product movement analysis
  • Fig. 32 Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Oral Topical Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Class I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Class II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Class III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Healthcare Contract Development and Manufacturing Organization Market: Service outlook and key takeaways
  • Fig. 48 U.S. Healthcare Contract Development and Manufacturing Organization Market: Service movement analysis
  • Fig. 49 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Preformulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Medical Devices & Combination Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow outlook and key takeaways
  • Fig. 62 U.S. Healthcare Contract Development and Manufacturing Organization Market: Workflow movement analysis
  • Fig. 63 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area outlook and key takeaways
  • Fig. 66 U.S. Healthcare Contract Development and Manufacturing Organization Market: Therapeutic Area movement analysis
  • Fig. 67 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 80 U.S. Healthcare Contract Development and Manufacturing Organization Market: End Use movement analysis
  • Fig. 81 Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key company categorization
  • Fig. 85 Service heat map analysis
  • Fig. 86 Strategic framework